Cefmatilen
Chemical compound
- none
- (6R,7R)-7-{[(2Z)-2-(2-amino-1,3-thiazol-4-yl)- 2-(hydroxyimino)acetyl]amino}-8-oxo-3-{[(1H-1,2,3- triazol-4-ylsulfanyl)methyl]sulfanyl}-5-thia-1- azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid
- 140128-74-1 Y
154776-45-1 (HCl · H2O)
- 9690121
- 4912110 Y
- T750UM24H8
- ChEMBL2104438
- DTXSID50161236
- Interactive image
- C1C(=C(N2[C@H](S1)[C@@H](C2=O)NC(=O)/C(=N\O)/C3=CSC(=N3)N)C(=O)O)SCSC4=NNN=C4
InChI
- InChI=1S/C15H14N8O5S4/c16-15-18-5(2-30-15)8(21-28)11(24)19-9-12(25)23-10(14(26)27)6(3-29-13(9)23)31-4-32-7-1-17-22-20-7/h1-2,9,13,28H,3-4H2,(H2,16,18)(H,19,24)(H,26,27)(H,17,20,22)/b21-8-/t9-,13-/m1/s1 Y
- Key:UEQVTKSAEXANEZ-YCRCPZNHSA-N Y
Cefmatilen (INN, codenamed S-1090) is an orally-active cephalosporin antibiotic. It was developed in Japan and first described in 1992.[1]
In vitro, cefmatilen is highly active against a variety of Gram-positive and Gram-negative bacteria, including Streptococcus pyogenes and Neisseria gonorrhoeae.[1]
References
- ^ a b Tsuji M, Ishii Y, Ohno A, Miyazaki S, Yamaguchi K (November 1995). "In vitro and in vivo antibacterial activities of S-1090, a new oral cephalosporin". Antimicrob Agents Chemother. 39 (11): 2544–51. doi:10.1128/aac.39.11.2544. PMC 162981. PMID 8585742.
Further reading
- Cazzola M (February 2000). "Novel oral cephalosporins". Expert Opin Investig Drugs. 9 (2): 237–46. doi:10.1517/13543784.9.2.237. PMID 11060674. S2CID 45932120.
- v
- t
- e
(inhibit synthesis
of peptidoglycan
layer of bacterial
cell wall by binding
to and inhibiting
PBPs, a group of
D-alanyl-D-alanine
transpeptidases)
Lipopeptides |
|
---|---|
Other |
|
- Inhibit PG subunit synthesis and transport: NAM synthesis inhibition (Fosfomycin)
- DADAL/AR inhibitors (Cycloserine)
- bactoprenol inhibitors (Bacitracin)
- Hydrolyze NAM-NAG
- Tyrothricin
- Isoniazid#
- Teixobactin
- #WHO-EM
- ‡Withdrawn from market
- Clinical trials:
- †Phase III
- §Never to phase III
This systemic antibiotic-related article is a stub. You can help Wikipedia by expanding it. |
- v
- t
- e